X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Cytiva and NecstGen form strategic collaboration to accelerate development of cell and gene therapies

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

    Cryoport and Cell Matters Enter into Strategic Partnership

    Cryoport and Cell Matters Enter into Strategic Partnership

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

    Gilead Sciences Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Australia Therapeutic Goods Administration Grants Provisional Registration for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Cytiva and NecstGen form strategic collaboration to accelerate development of cell and gene therapies

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

    Cryoport and Cell Matters Enter into Strategic Partnership

    Cryoport and Cell Matters Enter into Strategic Partnership

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

    Gilead Sciences Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Australia Therapeutic Goods Administration Grants Provisional Registration for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Facilities & Operation

Bayer HealthCare launches oncology treatment Xofigo in UK

Yuvraj_pawp by Yuvraj_pawp
14th January 2014
in Facilities & Operation

Bayer HealthCare has launched Xofigo (radium – 223 dichloride) solution for injection in the UK to treat adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.

The launch follows a positive recommendation from the European Committee for Medicinal Products for Human Use and the marketing authorisation by the European Commission (EC) for Xofigo based on results from the Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial.

In the UK, Prostate cancer is the most common cancer in men and in 2010, about 41,000 men were newly diagnosed with the disease. The company said that on average,10-20% of prostate cancer patients develop castration-resistant prostate cancer (CRPC) in about five years of follow up and 84% of them have metastatic disease at the time of diagnosis.

ALSYMPCA trial principal investigator and The Royal Marsden NHS Foundation Trust Consultant Clinical Oncologist Christopher Parker said, “The majority of men who develop castration-resistant prostate cancer will develop bone metastases which can be painful and even life-threatening.”

The clinical safety and efficacy of Xofigo have been assessed in a double-blind, randomized, placebo-controlled trial of Xofigo with best standard of care vs. placebo with best standard of care in symptomatic CRPC patients with bone metastases.

Around 921 patients in more than 100 centres in 19 countries were enrolled in the trial, which included about six intravenous injections of Xofigo or placebo each separated by an interval of four weeks.

Primary efficacy endpoint in the trial was overall survival (OS), while secondary endpoints included time to symptomatic skeletal events (SSE), alkaline phosphatase (ALP) and prostate-specific antigen progression (PSA).

Bayer Business Unit head Specialty Medicine Jon Hemphill said the launch and availability of Xofigo in the UK should be welcomed news for physicians and patients, who have been looking for new treatment options.

“With today’s announcement, we reinforce our commitment to working closely with physicians, patients and other stakeholders to meet the needs of this community,” Hemphill said.

According to the company, the trial was stopped early after a pre-planned efficacy interim analysis, following a recommendation from an Independent Data Monitoring Committee, on the basis of achieving improvement in overall survival.

At the interim analysis, Xofigo has improved OS, while median OS was 14.0 months with Xofigo plus best standard of care vs. 11.2 months with placebo plus best standard of care.

Additionally, there was a delay in the time to first SSE for patients treated with Xofigo vs. placebo. An updated analysis, carried out after the trial was unblinded, demonstrated a further improvement in OS for patients treated with Xofigo vs. placebo, with a median OS of 14.9 months vs. 11.3 months.

Xofigo also showed improvement in both analyses compared to placebo in the secondary endpoints of total time to ALP progression, time to PSA progression.

Previous Post

Some 'healthy' vegetable oils may actually increase risk of heart disease

Next Post

Tafinlar® receives FDA Breakthrough Therapy designation for non-small cell lung cancer with BRAF mutation

Related Posts

New Concept Allows Physical Partnering Event
Facilities & Operation

New Concept Allows Physical Partnering Event

11th September 2020
Pfizer and Flatiron Health Announce Expanded Strategic Collaboration to Unlock Power of Real-World Evidence in Oncology
Facilities & Operation

Pfizer and Flatiron Health Announce Expanded Strategic Collaboration to Unlock Power of Real-World Evidence in Oncology

27th September 2019
Catalent To Open New Clinical Supply Facility In San Diego
Drug Development

Catalent To Open New Clinical Supply Facility In San Diego

17th September 2019
IQVIA MedTech
Facilities & Operation

IQVIA Launches IQVIA MedTech Dedicated to Medical Device and Diagnostics Industry

14th May 2019
Catalent Invests $14 Million At Its Eberbach, Germany Softgel Facility
Facilities & Operation

Catalent Invests $14 Million At Its Eberbach, Germany Softgel Facility

24th April 2019
Blackstone Life Sciences and Novartis Launch Anthos Therapeutics to Develop Innovative Medicines for Cardiovascular Disease
Facilities & Operation

Blackstone Life Sciences and Novartis Launch Anthos Therapeutics to Develop Innovative Medicines for Cardiovascular Disease

1st March 2019
Next Post

Tafinlar® receives FDA Breakthrough Therapy designation for non-small cell lung cancer with BRAF mutation

Latest News

NIH begins study of allergic reactions to Covid-19 vaccines
News

To Treat COVID WHO Approves Monoclonal Antibody Tocilizumab

18th February 2022
Envirotainer introduces the RAP for the future - part of the Releye series
Packaging & Logistic

Envirotainer introduces the RAP for the future – part of the Releye series

14th February 2022
United Cargo Meets Growing Demand for Pharmaceuticals with New TempControl Containers
Packaging & Logistic

Opticooler receives technical approval by Japanese major airlines

14th February 2022
Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease
Press Statements

Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease

14th February 2022
Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
News

Indian Scientists Claim To Design Vaccine For All Variants

9th February 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In